Skip to main content

Armata Pharmaceuticals, Inc.

corporate_fare Company Profile

Armata Pharmaceuticals, Inc.

ARMP·NYSE·Life Sciences·CIK 0000921114

Armata Pharmaceuticals, Inc. is a late clinical-stage biotechnology company focused on developing high-purity and potency, pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company has completed three Phase 2 clinical trials to date. Armata views bacteriophages, or "phages," as a potentially safer and effective alternative to antibiotics and an essential response to growing bacterial resistance to current classes of antibiotics. Phages have a mechanism of action that enables binding to and killing of specific targeted bacteria while preserving the normal human microbiome, or "healthy bacteria." This contrasts with traditional broad-spectrum antibiotics, which can alter the human microbiome and increase susceptibility to opportunistic pathogens, such as Clostridium difficile. Armata believes phages represent a promising means to treat bacterial infections as an alternative to broad-spectrum antibiotics, especially for patients with bacterial infections resistant to current standard of care therapies, including multidrug-resistant or "superbug" strains of bacteria. Armata combines its proprietary approach and expertise in identifying, characterizing and developing both naturally occurring and engineered bacteriophages with its proprietary phage-specific host-engineered cGMP manufacturing capabilities to advance a clinical pipeline of bacteriophage product candidates. The company is advancing two distinct clinical candidates, AP-PA02 and AP-SA02, targeting two different bacterial pathogens, with the potential to treat chronic pulmonary disease complicated by bacterial infection as well as acute systemic bacterial infection. To date, Armata has completed three Phase 2 randomized, double-blind, placebo controlled clinical trials. The company has combined its clinical data with in vitro science to extend its knowledge of phage biology and enhance in vivo phage function. Armata has also improved its manufacturing processes, significantly increasing phage titers and purity and improving production efficiency.

Armata Pharmaceuticals, Inc. (NYSE:ARMP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for ARMP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 8/10. Recent SEC coverage for ARMP spans 10-Q.

Recent high-impact activity:

  • Armata 10-Q: $54.9M Q3 Net Income Is Non-Cash; Going Concern Flagged on $18.3M Cash

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$173.8M
Diluted EPS
-$4.80
Op. Cash Flow
-$25.76M
Free Cash Flow
-$26.3M
Operating Income
-$36.63M
Cash & Equivalents
$8.69M
Total Debt
$153.86M
Debt / Equity
-0.70×
Shares Outstanding
36.43M sh
Source: 10-K · filed 2026-03-25 · accession 0001104659-26-034532

Short Interest & Short Volume

9.78 days to cover

FINRA reported short interest of 912,610 shares in ARMP as of the October 30, 2026 settlement, a 1.4% increase from the prior period — about 9.8 days to cover at its recent average daily volume. On November 20, 2026, 59.7% of ARMP volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)912,610 shares as of October 30, 2026
Change vs prior period▲ 1.4%
Days to cover9.78 at avg daily volume of 93,354
Daily short volume (FINRA facilities)59.7% of 24,880 shares on November 20, 2026
5-day average short volume70.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$2.99 -1.32% today
52-week range · as of 2026-11-12 $2.75 – $14.98
Market cap
$112.69M
Volume
85.9K (0.9× avg)
3-mo avg 94.8K
Live data · 2026-11-21 17:30 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ARMP - Latest Insights

ARMP
Nov 12, 2026, 4:26 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.72
Real-time Price: $2.99 info
Change: -$0.730 (-20%) info
Market Cap: $112.694M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets